en تخصصي Special پژوهشي Research <div style="text-align: justify;"><span style="font-size:14px;"><span style="font-family:Times New Roman;"><span style="line-height:14.0pt"><b><span style="color:#24a3a0">Background and Objective:</span></b> <span style="color:#000000;">Liver disorders in hematological malignancies cause treatment delays and, as a result, disease recurrence. The aim of this study was to evaluate the survival and prognosis of children and adolescents with hematological malignancies and liver involvement after chemotherapy.</span></span><br> <span style="line-height:14.0pt"><b><span style="color:#24a3a0">Methods:</span></b> <span style="color:#000000;">This cross-sectional study was conducted in the Hematology and Oncology Department of Mardani Azar Children&rsquo;s Hospital, Tabriz University of Medical Sciences, by reviewing the files of patients hospitalized from December 22, 2021 to December 22, 2023. The study included hospitalized children with hematological malignancies. Demographic information, treatment stage, and liver test results were recorded before and after chemotherapy. Survival modeling was performed from the time of diagnosis to the occurrence of outcomes, including relapse, disease remission, complete recovery, and mortality, using the Kaplan&ndash;Meier method. Data were statistically analyzed using SPSS 26. A value of P<0.05 was considered significant.</span></span><br> <span style="line-height:14.0pt"><b><span style="color:#24a3a0">Findings:</span></b> <span style="color:#000000;">In this study, out of 150 patients, 55 (36%) had elevated liver enzyme levels. During the clinical and laboratory follow-up, one patient achieved complete recovery, 27 patients had remission, and 21 patients experienced relapse. The mortality rate was 1.9%. The survival rate among patients with liver damage was 87%. The survival probability for patients with liver damage was 0.95 after 7 months, 0.89 after 10 months, and decreased to 0.45 after 21 months.</span></span><br> <span style="line-height:14.0pt"><b><span style="color:#24a3a0">Conclusion:</span></b> <span style="color:#000000;">The mortality rate was higher in patients whose treatment was discontinued due to prolonged elevation of liver enzymes than in those whose liver damage improved and who continued malignant treatment.</span></span></span></span></div> Chemotherapy, Hematologic Malignancies, Liver Enzymes 0 0 http://caspianjp.ir/browse.php?a_code=A-10-348-1&slc_lang=en&sid=1 Abbas Ali Hosseinpour Feizi pourfeizi@yahoo.com 10031947532846005161 10031947532846005161 No Department of Pediatrics, School of Medicine Hematology and Oncology Research Center Clinical Research Institute Children Medical Research & Training Hospital Tabriz University of Medical Sciences Maryam Shoaran maryamshoaran@yahoo.com 10031947532846005162 10031947532846005162 No Department of Pediatrics, School of Medicine Tabriz University of Medical Sciences, Tabriz, Iran Saeed Dastgiri saeed.dastgiri@gmail.com 10031947532846005163 10031947532846005163 No Department of Community Medicine, School of Medicine, Tabriz Health Services Management Research Center,Health Management Research Institute,Tabriz University of Medical Sciences, Tabriz, Iran Yousef Tavakolifar yuosef.ta@gmail.com 10031947532846005164 10031947532846005164 No Department of Pediatrics, School of Medicine Tabriz University of Medical Sciences, Tabriz, Iran Amir Ataollah Hiradfar hiradfara@gmail.com 10031947532846005165 10031947532846005165 No Department of Pediatrics, School of Medicine Tabriz University of Medical Sciences, Tabriz, Iran Fatemeh Amri Fatemeamri22@gmail.com 10031947532846005166 0009-0000-7125-7055 Yes Department of Pediatrics, School of Medicine Tabriz University of Medical Sciences, Tabriz, Iran Parviz Amri pamrimaleh@gmail.com 10031947532846005167 10031947532846005167 No Babol University of Medical Sciences, Gangafrooz Street, Daneshgah Square, Babol, Mazandaran, Iran